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Abstract
Background: It is essential to allocate available resources equitably in order to ensure accessibility and affordability
of essential medicines, especially in less fortunate nations with limited health funding. Currently, transparent and
evidence based research is required to evaluate decision making regarding drug registration, drug pricing and
reimbursement processes in Mongolia.
Objective: To assess the drug reimbursement system and discuss challenges faced by policy-makers and stakeholders.
Methods: The study has examined Mongolian administrative documents and directives for stakeholders and analysed
published statistics. Experts and decision-makers were interviewed about the drug pricing and reimbursement
processes in Mongolia.
Results: Decisions regarding Mongolian drug registration were based on commonly used criteria of quality,
safety, efficacy plus some economic considerations. A total of 11.32 billion Mongolian National Tugrugs (MNT)
[5.6 million United States Dollars (USD)] or 12.1% of total health expenditure was spent on patient reimbursement of
essential drugs. The highest reimbursed drugs with respect to cost in 2014 were the cardiovascular drug group. Health
insurance is compulsory for all citizens; in addition all insured patients have access to reimbursed drugs. However, the
decision making process, in particular the level of reimbursement was limited by various barriers, including lack of
evidence based data regarding efficacy and comparative cost-effectiveness analysis of drugs and decisions
regarding reimbursement.
Conclusions: Drug registration, pricing and reimbursement process in Mongolia show an increasing trend of
drug registration and reimbursement rates, along with lack of transparency. Limited available data indicate that
more evidence-based research studies are required in Mongolia to evaluate and improve the effectiveness of
drug pricing and reimbursement policies.
Keywords: Drug pricing policy, Reimbursement, Cost, Pharmaceuticals, Mongolia
Introduction
Mongolia is an East-Asian country bordered with Russia
and China. It is the 19th largest country in the world
with an estimated area of 1,566,460 km2. After the col-
lapse of the Soviet Union, Mongolia has undergone rad-
ical change in financial support for health, education
and social security. Despite steady economic growth
with promising developments occurring in the last
15 years, recent statistics show that infectious diseases
are no longer the leading cause of morbidity, instead
lifestyle, behaviour –dependent diseases, including circu-
latory system diseases, cancer and injuries have become
the leading causes of mortality and morbidity [1].
During the years of socioeconomic transition in
Mongolia, total health expenditure (THE) as a share of
Gross Domestic Product (GDP) has increased from 3.3%
(1995) to 5.4% by 2010 [2, 3].
Despite existing government regulations, inappropri-
ate use of medicines [4] and high drug costs are evident
in Mongolia [5]. Although illegal, people can purchase
prescription medicines, including antibiotics without
prescription from some private pharmacies [6, 7]. Previ-
ous reports have indicated lower out of pocket (OOP)
expenses with about 10% of outpatients and 16% of
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inpatients paying OOP fees for hospital visits in 2011
[8]. However, the study did not specify whether these
fees were for medicines or treatment.
Overview of the Mongolian health sector
The Mongolian health sector is regulated by the Ministry
of Health (MOH), the Ministry of Finance (MOF), the
Ministry of Human Development and Social Welfare
(MOHDSW), the Ministry of Education and Science
(MOES), the regulating agency -General Agency for
Specialised Inspection (GASI) and former government
implementing agencies such as the Department of
Health (DOH), the Department of Physical Culture and
Sport (DOPS), and the city/aimag (provincial) health
departments.
The MOH and MOHDSW are the third-party payers
involved in purchasing and resource allocation in
health care. The government health budget is managed
by the MOH, and the Health Insurance Fund is man-
aged by Social Insurance General Office (SIGO- under
the MOHDSW). The fund for social health insurance
(HI) is a single national insurance fund that uses its
local branches to collect revenue and pay for insured
care and it has been a stable source of health financing
in Mongolia since 1990s. In addition to having govern-
ment agency status, the SIGO is also overseen by the
Social Insurance National Council (SINC) appointed by
the State Great Khural.
Despite having a low share of THE, it is the only
health financing mechanism that exercises some ele-
ments of contracting and purchasing. The government is
the dominant player in making HI decisions therefore it
is used as a substitute for the government budget.
Pharmaceutical sector in Mongolia
The Division for Pharmaceutical and Medical Devices of
the MOH is responsible for oversight of the main func-
tions of the pharmaceutical sector policy, regulation and
coordination. The Division for Health Inspection of the
General Agency for Specialized Inspection ensures com-
pliance with major laws and legislation as it relates to
quality assurance and distribution inspection. A Human
Drug Council consisting of experts in the field and rep-
resentatives of all relevant ministries leads the pharma-
ceutical sector, particularly in the development of
standards, guidelines and procedures, including drug
registration. The Drug Regulatory Unit is responsible
for technical work for the Human Drug Council includ-
ing the registration of medicines and medical devises,
licensing of specialists and providers, issuance of im-
port and export licenses, monitoring and reporting ad-
verse drug reactions, monitoring medicines marketing
and advertisement, promoting rational use of medicines
and developing a national pharmacopeia and standards.
In addition, a Special Permission Committee of the
MOH monitors the functional activities of drug pro-
ducers and grants approval for manufacturing, import-
ing and selling drugs in Mongolia (Figs. 1 and 2).
The drug reimbursement decision is approved by the
Health Insurance Fund (HIF), which is incorporated
within the General Department of Social Insurance and
it is regulated by the Ministry of Human Development
Social Welfare of Mongolia.
The Drugs Act of Mongolia was promulgated in
1998 and aimed to ensure good quality, effective and
safe drugs were available to the Mongolian population.
Following the Drug Act, the National Drug Policy of
Mongolia (NMPM) was adopted in 2000, revised and
approved by the State Great Khural in 2014. Minister-
ial legislation corresponding to reimbursement in-
cludes the Health Insurance Law, approved by the
State Great Khural 2015 and the Resolution on the List
of Essential Medicines to be reimbursed by the HIF,
approved by the National Committee on Social Insur-
ance of Mongolia in 2016.
The Policy regulates the procurement, manufacturing,
financing, quality assurance, distribution, and appropri-
ate use of drugs. In order to ensure the availability of the
most essential medicines at all levels, the government
has adopted an Essential Drugs List, developed on the
basis of recommendations by the World Health
Organization (WHO). This List has been available since
1991 and it has been revised several times with the sev-
enth being completed in 2014 [9].
The procurement of health products including medi-
cines for only public health facilities (hospital pharma-
cies) is regulated by the Law on Public Procurement
and Guidelines approved by the MOH. Tertiary-level
health facilities and aimag health departments have
their own tendering committees. Ulaanbaatar city car-
ries out a tender for all its district hospitals in the
urban area. Medicines procured and sold at private re-
tail pharmacies are supplied by wholesaling companies,
however the government has no regulation on price.
The Mongolian pharmaceutical sector is predomin-
antly dependent on its manufacturing and private busi-
ness organizations due to 100% privatization of all
pharmaceutical wholesalers. Mongolia was defined as a
low-income country with THE of 556 billion MNT or
2.6% of GDP in 2013 [10], hence evidence based deci-
sion making and optimum use of available resources is
of high importance.
Drug distribution system in Mongolia
Most of the imported drugs sold in Mongolia come from
the Russian Federation, China, India and other eastern
European countries. Drug supply companies and phar-
macies must be licensed in order to undertake drug
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supply functions. With the accelerating growth of the
private sector, the drug supply business has proven to be
very successful. Currently, 1190 pharmacies are operat-
ing all over Mongolia and 75% of the private pharmacies
have one or two branches. There were 306 pharmacies
working under the drug revolving fund (DRF) initiative
[1]. According to the latest report, 24 drug factories
were officially permitted to operate as drug manufac-
turers and their share was approximately 12% (66 Billion
MNT) of the total local pharmaceutical market [11].
There were 591 new drugs (salts or dosage forms), 48
raw materials registered and the registration period was
extended for a total of 428 drugs in 2014 [11].
The latest survey on medicines prices and affordabil-
ity in Mongolia was completed using WHO method-
ology in 2010 and it reported that the affordability of
the lowest priced generics and most sold generics in
the public sector was good for most conditions, with
standard treatment costing 1 days' wage or less. Treat-
ments costing more than 1 days' wage of the lowest
paid unskilled government worker included a pack of
30 amlodipine tablets to treat hypertension (1.6 days)
[5]. In the private sector, the majority of treatments
cost less than the daily wage of the lowest paid govern-
ment worker when the lowest price generics were used.
Hypertension treated with enalapril (10 mg cap/tab) for
30 days costs 2.5 days’ wages, simvastatin (20 mg cap/
tab) 30 days 2.7 days’ wages are clearly unaffordable
even when generics are used.
The price of medicines has not been regulated by the
Government since 1997 and a 10% value-added- tax
(VAT) was introduced in 1999. Taxes, duties and other
government charges applied to medicines include 5%
customs duty for imported medicines. In the private
sector, add-on costs represent 90.1% of the final pa-
tient price for imported originator brands, 115.5% for
imported generics, and 74.4% for locally produced
generics. Registration fees do not differ between
originator brands and generic equivalents. However,
registration fees are lower for locally produced than
for imported medicines; hence the government en-
courages local production.
Fig. 1 Organizational structure of the Mongolian pharmaceutical policy and regulation. Note: Human Drug Council and Special Permission
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Fig. 2 Proportion of reimbursed drugs, by pharmacological classification (Billion MNT), 2014 (adapted from Health Indicators of Mongolia, 2014)
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There are no public pharmacies, except those located
in public hospitals whose service is limited to inpatients.
Furthermore, the government controls dispensing fees
for reimbursed essential medicines and some data are
available to support the insurers view on the dispensing
fee.
The drug reimbursement system and health insurance
scheme have been developed since 1994. The latest re-
vision of the list for reimbursed essential drugs was ap-
proved by the SHI in 2016 [12]. The main purpose was
to expand the range of health insurance benefits and
ensure greater access to essential drugs in primary
health-care services by the insured population which is
compulsory for all population groups [12].
To date, insured ambulatory patients have access to a
total of 134 essential drugs partly reimbursed by the
Health Insurance (HI) providing that these drugs were
prescribed by a family doctor (in urban settings), village
(soum) hospital doctor or district (bagh) feldsher (in
rural settings) and dispensed by a HI designated or
contracted pharmacy.
A list containing the cost of certain essential drugs is
also available once it has been approved by the HI. This
list gives the maximum price level for certain drugs
provided to insured ambulatory and stipulates how
much of this cost should be covered under HI. A deci-
sion to include the drug in the reimbursement list is
based on mortality and morbidity rates for the last
2 years and drug consumption listed by pharmaco-
logical classification. No further information of specific
analysis for reimbursement decision making was
available.
Drug reimbursement funding is an important expend-
iture to ensure the budget is used optimally. However,
there is a lack of detailed information in regards to
drug pricing and reimbursement decisions in Mongolia.
Considering the importance of clear and transparent
processes for drug pricing and government funded re-
imbursement, this study has aimed to examine the
pharmaceutical drug pricing and reimbursement deci-
sion making in Mongolia.
Methods
Documents relevant to drug reimbursement
Existing documents regarding drug reimbursement, se-
lection and procurement of essential medicines, appro-
priate use of medicines including regulations enacted
by the Mongolian Government, legislative documents
and published internal regulations of the Human Drug
Council, Ministry of Health of Mongolia (MOH), Phar-
maceuticals and Medical Devices Division, (MOH),
Social Health Insurance Office (SHIO), and the Div-
ision of Finance and Insurance, the Ministry of Finance,
Mongolia (MOF), including approved State Policy on
Medicines and Medical Devices (2014), Health Law
(2010), regulation to reimburse essential medicines by the
Health Insurance, approved by the Health Insurance Sub-
committee, National Social Insurance Committee, #03,
2011, anupdated list of reimbursable essential medicines,
Health Insurance Subcommittee, National Social Insur-
ance Committee (2013.07.31), General requirement for
pharmacies in Mongolia, MNS 260:2011,#13 Regulation
for registration of medicines, raw materials, biologically
active compounds in Mongolia, approved by the Health
Minister, 2015 were reviewed by all authors in this study.
More documents in relation to the statistics and published
data related to drug pricing and drug reimbursement,
published and unpublished annual reports reimbursement
of medicines, including Mongolian statistical annual re-
port, National Statistical Office, Annual report of Health
Insurance Office, Survey of medicine prices, availability,
affordability and price components in Mongolia, 2012 [5]
were collected and reviewed.
In addition, websites of several organisations and agen-
cies including drug regulatory authorities were examined
for relevant information and reports. The search was
complemented by hand searches of bibliographies and,
in the case of doubt, by telephone and email communi-
cation with the institutions themselves.
Interviews
In order to collect more detailed information on the de-
cision making process and evaluation methods, key
stakeholders including the authorities and officers in
charge of drug registration, procurement and reimburse-
ment including the Head of Pharmaceuticals and Med-
ical Devices Division, Health Insurance Office, Head of
Allocation and Monitoring of Health Budget, Ministry of
Finance, Human Drug Council Member, Officer in
charge for drug procurement services, policy implemen-
tation, MOH were interviewed. The interview consisted
of questions regarding information about the respondent
[13] and reimbursement, including the (i) assessment,
(ii) appraisal and (iii) decision making processes. Assess-
ment included the quantification of the clinical, pharma-
cotherapeutic efficacy and pharmacoeconomic value of a
drug. Appraisal sought to gauge society’s willingness to
pay for a drug by weighing assessment outcomes against
other (societal) criteria which reflect health system ob-
jectives. Decision making was defined as a value judge-
ment from a broader societal perspective, considering
the health system policy objectives as well as non-health
care related objectives.
The interview guide (in Mongolian) was piloted with
four potential respondents to ensure the validity; tech-
nical functioning, relevance and understanding of the
questions. No major omissions were identified. These re-
sponses were not used further in the study.
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As Mongolian versions of the documents are avail-
able, the study engaged two professional translators to
complete translations from Mongolian to English and
vice-versa to assure accuracy and minimize any possible
bias. These translators were unknown to each other
[14]. The author made adjustments resulting from any
inconsistencies. (Data are available upon request from
the corresponding author).
Data analysis
Standard descriptive statistics were used to summarize
demographic data and responses to the interviews.
Questions regarding the frequency of assessment, ap-
praisal and decision making were answered. All docu-
ments were analysed in a qualitative matter and
according to an analytic informational framework that
had been developed in advance. Results were sum-
marised narratively and presented in a related manner.
Comparisons between groups were performed using
the Chi-square test, logistic regression or Kruskal–
Wallis test with a pairwise comparison as appropriate.
A p value of <0.05 was taken as being significantly
different.
Results
Drug registration process in Mongolia
All drugs used in the country are registered once agree-
ment and authorization by the Human Drug Council
has been given. The General Agency for Specialized
Inspection (GASI) is in charge of ensuring that only reg-
istered drugs enter the market for public use. Locally
manufactured drugs are registered for 2 years, whereas
imported drugs are given a 4-year (regular registration)
or 5-year (fast-track registration) period. The drugs
should be of a good quality, compliant with good
manufacturing practice (GMP) regulations to qualify
for registration. The applicant must prepare documents
including data regarding efficacy, safety and adverse
events, comparative efficacy with similar drugs, approval
history, contraindications, warnings, precautions, moni-
toring parameters, pharmacokinetics, patient compliance
and information of cost, insurance and freight (CIF) cost
for registration.
All medicines should be registered in the State Medi-
cines Register which is divided into two categories as
medicines available with and without prescription (over-
the-counter, OTC).
Drug reimbursement process in Mongolia
Detailed analysis of HI statistics indicates that 11.32 Billion
MNT (5.59 Million USD) was spent on reimbursement of
essential drugs, and that half of the reimbursement was
spent on cardiovascular agents (5.579 Billion MNT) in
2014 (Table 1). Considering the health indicators, the
prevalence of cardiovascular diseases is listed as priority
causes of mortality and morbidity [1].
A detailed analysis of reimbursed cardiovascular
drugs indicated that the highest was for amlodipin
(3,059,489,957 MNT) and the lowest was for enalapril
(69,266 MNT). In terms of analgesics, antipyretics,
non-steroidal anti-inflammatory drugs, the most reim-
bursed item was ibuprofen syrup 9,205,575,118 MNT)
and the least dispensed item with reimbursement was
paracetamol tablets (12 pack, 140,486 MNT) (Table 1).
The proportion of pharmaceutical expenditure has
been relatively stable ranging from 12 to 14% of total
health expenditure in the last 5 years, whereas the reim-
bursement provided by the HI has steadily increased
over the last 6 years. The revised list of reimbursable es-
sential medicines contained a total of 134 medications
prescribed by a legal prescriber/physician the reimburse-
ment level has ranged from 40 to 83.3% of the cost of
the medicine. This list indicates the maximum retail
price that a retail pharmacy can charge. This indicates
that the government is fixing the total cost of these med-
icines charged by retail pharmacies.
The latest statistics indicate that the population cover-
age has increased to 99% which means essentially the
whole population is covered for essential drugs [1].
Until 2014, there were no price control mechanisms
specific to generic drugs, however the latest revision of
the NDPM indicates that the maximum price of essen-
tial medicines shall be regulated by the Government
[15]. Therefore the only price control is on reimbursed
essential medicines in Mongolia.
Discussion
This study has indicated that the Mongolian drug
registration process is based on commonly used deci-
sion making criteria that are applied in many countries
[13, 16]. These criteria include safety, efficacy and
some economic aspects. Official reports and docu-
ments also have shown that Mongolian HI operates
with some advantages, including a 92.2% of insurance
coverage in Mongolia [2]. However, due to low pay-
ment in regards with salary (lowest: 192000 MNT or
101.3 USD) and pension (lowest: 145.200 MNT or 87
USD), the health care benefits of an estimated 1.33
million MNT or 798 USD per person annually are re-
ported to be rather weak [17].
As acknowledged in many other countries, the drug
reimbursement process is a very challenging task shared
by various authorities with different interests [18]. The
Ministry of Health of Mongolia works towards delivering
quality health care and increased efficacy and accessibil-
ity of drugs to all patients, whereas the Ministry of
Finance and Ministry of Human Development and Social
Welfare aim to increase the health insurance coverage
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Table 1 Drug categories and reimbursement data for essential drugs for the year 2014

















1. Analgesics, antipyretics, non steroidalantiinflammatory drugs
1 Acetyl salycilic acid 100 mg tablet 100 1500 66,7 1000 1,145,655 11.4
10 3000 50 1500 4,041,900 4.9
30 2000 50 1000 432,918 1.4
150 mg 10 3500 57,1 2000 364,000 0.6
300 mg 10 5000 60 3000 14,472 4.3
2 Diclofenacsodium 25 mg tablet 10 750 66,7 500 22,714 4.6
50 mg 10 750 66,7 500 195,847 36.7
75 mg 10 7500 53,3 4000 0 0
100 mg 10 1500 66,7 1000 0 0
50 mg suppositorium 10 1500 66,7 1000 9912 0.9
100 mg 2 2500 80 2000 45,015 45.9
20 гp gel 1 4000 50 2000 0 0
3 Ibuprofen 200 mg tablet 12 5000 60 3000 115,355 28.8
400 mg 10 1500 66,7 1000 996,263 99.3
100 ml syrup 1 8500 58,8 5000 41,235 205.6
4 Indomethacin 25 mg tablet 30 1800 55,6 1000 51,436 2.6
20 1200 83,3 1000 0 0
5 Paracetamol 500 mg tablet 10 250 40 100 64,506 0.6
12 1200 50 500 3373 0.1
100 mg suppositorium 10 250 57,1 2000 13,264 2.6
100 ml suspension 1 1000 61,5 4000 1015 4.1
3%-90 ml syrup 1 3500 50 3000 529 1.6
6 Tramadol 50 mg tablet 10 3300 60,6 2000 88,245 17.6
Sub total 7,647,654 473.8
5.2 Antiinfective agents
5.2.1 Beta-lactame antibiotics
25 Amoxicillin 125 mg syrup 1 4000 50 2000 3547 7.4
250 mg 1 7000 57,1 4000 293,886 30.1
125 mg 10 5000 60 3000
250 mg 10 1500 62,5 1000 293,886 30.1
500 mg 10 2000 50 1000 5,062,806 56.9
26 Amoxicillin + clavulanic
acid
100 ml syrup 1 10,000 50 5000 1799 8.9
156.25
mg/5 ml
1 8100 61,7 5000 5179 25.8
228.5
mg/5 ml
1 7200 69,4 5000 602 3
125 mg/60 ml 1 5000 80 4000 1980 7.9
156.25 mg tablet 10 7500 60 4500 5179 25.8
312.5 mg 10 10,000 50 5000
375 mg 16 15,200 52,6 8000
625 mg 10 16,000 62,5 10,000 442,351 439.8
27 Phenoxymethylpenicllin 250 mg tablet 10 850 58,8 500 6800 0.3
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Table 1 Drug categories and reimbursement data for essential drugs for the year 2014 (Continued)
28 Cefadroxil 500 mg capsule/tablet 10 3800 65,8 2500 8244 2.1
Sub-total 6,126,259 638.4
5.2.2 Other antiinfectiveagents
29 Clarithromycin 500 mg tablet 14 21,000 47,6 10,000 494,548 351.9
250 mg 14 15,400 51,9 8000 145,636 83.2
30 Doxycycline 100 mg capsule/tablet 10 2150 69,7 1500 21,097 3.2
31 Metronidazole 250 mg tablet 10 350 85,7 250 147,898 3.7
500 mg 10 1500 71,4 1000 67,655 10.8
500 mg suppositorium 6 3000 66,7 2000 2199 0.7




480 mg tablet 10 1000 50 500 85,087 43.2
240 mg/5 ml-
60 ml
suspension 1 2500 80 2000 949 3.1
34 Ciprofloxacin 250 mg tablet 10 3000 66,7 2000 98,752 46
500 mg 10 4500 66,7 3000
35 Azithromycin 100 mg-5 ml suspension 1 11,600 69 8000 7245 58
250 mg capsule 10 9000 55,6 5000 1,134,303 63
200 mg/5 ml-
20 ml
suspension 1 15,000 66,7 10,000
Sub total 2,350,389 681
5.3 Antifungal agents
36 Griseovulvin 125 mg capsule 10 800 62,5 500 868 0.04
37 Fluconazol 50 mg capsule 7 9100 54,9 5000 155,658 111.1
38 Clotrimasol 100 mg vaginal tablet 6 3000 66,7 2000 38 0.08
500 mg 1 3500 57,1 2000
20гp cream 1 2500 80 2000 296 0.6
15гp 1 2200 68,2 1500 84 0.1
10гp 1 2800 71,4 2000 146 0.3
39 Nystatin 500,000 unit Coated tablet 20 2500 80 2000 3620 3.6
500,000 unit Vaginal
suppositorium
10 2800 71,4 2000 1704 0.3
2,500,000 unit 10 2600 76,9 2000 10,475 2.1
Sub total 172,889 118.3
5.4 Antiviral agents
40 Aciclovir 200 mg tablet 20 4500 66,7 3000 120,741 19.5
5%-5гp ointment 1 3000 66,7 2000 2044 4.1
5%-2гp cream 1 12,500 80 10,000 1020 10.2
41 Ribavirin 200 mg capsule 20 12,000 66,7 8000 5760 2.3
42 Lamivudin 150 mg tablet 10 6000 66,7 4000 355 0.1
Sub total 129,920 36.1
6. Medication for migraine prophylaxis
43 Propranolol 40 mg tablet 50 3000 66,7 2000 40,677 1.6
Sub total 40,677 1.6
9. Drugs acting on blood
9.1 Hematinic agents
49 Ferlatum 60 mg tablet 10 1500 66,7 1000 7501 0.8
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Table 1 Drug categories and reimbursement data for essential drugs for the year 2014 (Continued)
50 Ferrovitum 162 mg +
0.75 mg +
7.50 mg
capsule 30 5400 55,6 3000 121,772 12.2
51 Folic acid 5 mg tablet 100 4000 50 2000 31,828 0.6
Sub total 161,101 13.6
10. Cardiovascular agents
10.1 Drugs for Angina pectoris, schemic heart diseases
52 Atenololum 50 mg tablet 30 3000 66,7 2000 330,066 21.9
100 mg tablet 10 2000 50 1000 31,812 3.2
53 Verapamilum 40 mg tablet 50 3500 57,1 2000 16,038 0.6
54 Glycerilumtrinitratum 6.4мu tablet 25 4750 63,2 3000 5082 0.6
55 Isosorbidumdinitratum 5 mg tablet 20 900 55,6 500 80,812 2
56 Nifedipinum 10 mg tablet 50 2500 80 2000 809,139 32.3
57 Inozinum 200 mg tablet 50 2200 68,2 1500 1,250,837 37.4
Sub total 253,786 98
10.2 Drugs for arrhythmia
58 Amiodarone 200 mg tablet 30 7500 66,7 5000 50,865 8.5
10.3 Antihypertensives
59 Hydrochlorthiazidum 25 mg tablet 30 3000 66,7 2000 7869 0.5
10 1200 83,3 1000 6557 0.6
60 Methyldopa 250 mg tablet 50 12,000 66,7 8000 60,237 9.6
61 Amlodipin 5 mg tablet 30 16,200 61,7 10,000 1,578,754 525.8
10 mg tablet 30 30,000 50 15,000 6,135,264 3059.5
62 Enalapril 2.5 mg tablet 20 3000 66,7 2000 25,525 2.5
5 mg tablet 30 3900 76,9 3000 310 0.1
10 mg tablet 30 5400 74,1 4000 1260 1.7
20 mg tablet 30 8100 61,7 5000 1580 2.4
63 Lozartan 25 mg tablet 28 10,500 76,2 8000 190,397 54.4
50 mg tablet 28 14,000 71,4 10,000 1,105,003 393.7
100 mg tablet 28 28,600 52,4 15,000 0
64 Lizinopril 5 mg tablet 14 5500 54,5 3000 0
10 mg tablet 14 7000 57,1 4000 0
20 mg tablet 14 8500 58,8 5000 0
Subtotal 9,112,756 405.9
10.4 Heart failure
65 Digoxin 250mkg tablet 30 3000 66,7 2000 6269 0.4
Sub total 6269 0.4
10.5 Lipid lowering drugs
67 Simvastatin 10 mg tablet 30 13,200 60,6 8000 65,260 17.4
20 mg tablet 30 22,000 45,5 10,000 322,778 107.6
40 mg tablet 30 36,000 50 18,000 587,264 352.3
Sub total 975,302 477.3
14. Diuretics
77 Spirinolactone 25 mg tablet 20 4200 71,4 3000 344,164 51.5
78 Furosemide 40 mg tablet 30 800 62,5 500 23,333 38,410
Sub total 346,497 38461.5
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with limited health funding. However, HI involvement in
the decision making process, the use of evidence-based
data, including post marketing analysis, cost-effectiveness
analysis are lacking. The different aspects and number of
various institutions involved leads to complexity in the
current system which can have a negative impact on
health care delivery, including increased OOP payment
for drugs. Obviously, this is a major point where the vast
array of government departments and offices involved
must make the system fragmented and avoid much
duplication.
The funding source of pharmaceuticals in Mongolia
was analysed and the non-government sources including
the donor organizations and patient OOP, played a min-
imal role for total pharmaceutical expenditure (TPE)
(4.8%) whereas government sourced fund (tax) was the
highest (80.4%) [19]. No data are available on private
health funds in Mongolia. Previous findings reported
that OOP payments for health services have increased
from 14.5% of the THE in 1995 to 41.4% in 2010. How-
ever, data in regards to OOP payments for pharmaceuti-
cals were not available [19, 20]. The WHO reviewed the
total expenditure on pharmaceuticals in different coun-
tries and compared by GDP. The median expenditure
for pharmaceuticals in European region was 13% and
Asian countries spent approximately 35% of total health
expenditure on pharmaceuticals. However, the data rep-
resent both public and pharmaceutical expenditure
[20]. The comparison of proportion of pharmaceutical
expenditure in different regions indicated that Mongolia
had the lowest public pharmaceutical expenditure (11.6%)
[20].
It is widely accepted that modern health technology
assessment methods should be used in such processes
[21]. Successfully implemented health technology assess-
ment programs including the evaluation of efficacy,
comparative cost-effectiveness of medical interventions
and published clinical guidelines as can be seen in
Australia [22], Canada [23] and UK [23]. Even though it
is difficult to create a system that satisfies all stake-
holders, the Mongolian pharmaceutical sector needs to
expand its assessment processes and report more rele-
vant data in order to allow the analysis of the pharma-
ceutical sector and develop coordinated systems for
decision making in drug reimbursement.
Limitations
The lack of evidence-based data on private health fund
and OOP payment for pharmaceuticals as well as the
price components for locally produced or imported
medicines, including lack of cost-effectiveness data limit
Table 1 Drug categories and reimbursement data for essential drugs for the year 2014 (Continued)
21. Vitamins and minerals
125 Ascorbucacidm 50 mg tablet 10 200 50 100 0
126 Vitamin B complex 100 mg +
200 mg +
300mkg








tablet 10 3600 76,9 2000 88,708 17.6
127 Calcium gluconate 500 mg tablet 10 250 40 100 59,066 0.6
128 Calcium
glycerphosphate
500 mg tablet 10 1200 83,3 1000 18,354 0.2
129 Polivitamine 50 mg dragee 50 300 33,3 100 78,739 0.2
150 mg syrup 1 8000 50 4000 66,666 264.4
500 mg Coatedtablet 10 1200 83,3 1000 18,794 1.9
130 Nicotinamide 50 mg tablet 10 800 62,5 500 15,518 0.8
131 Pyridoxine 20 mg tablet 10 400 75 300 740 0.02
132 Retinolumpalmitatum 20 mg dragee 10 1100 45,5 500 18,678 0.9
12,000 IU capsule 10 900 55,6 500 10,868 0.5
133 Ergocalciferol 15,000 IU
1 ml
solution 1 4500 66,7 3000 553 1.7
134 Thiamine 50 mg tablet 700 71,4 500 1150 0.1
Sub total 88,708 17.6
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study results to generalize for the pharmaceutical sector
in Mongolia.
Conclusions
Drug pricing and reimbursement of essential medicines
is an important task shared by many different author-
ities, including Ministry of Health and Sport and Minis-
try of Finance in Mongolia. Periodical reports of the
drug registration process, average registration duration
and decisions for drug registration are available. How-
ever, there is a lack of publicly available reports for the
reimbursement decision making process, whereas only
information related to drugs that can be reimbursed is
made publicly available once consensus has been
reached. Price negotiation, budget impact and cost-
containment are essential elements for a drug reimburse-
ment process. To allocate resource efficiently in Mongolia
is an important and challenging task. Currently the overall
system is too complex and there is a lack of accessible data
to permit a detailed analysis of the pharmaceutical sector,
which is necessary to drive decisions.
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